Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. A novel prosurvival model for cancer under environmental challenge: The "heart-felt" message for therapeutic intervention A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. A proteomic analysis of transplanted liver in a rat model of chronic rejection Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm Advances and challenges in basic and translational research on clusterin Advances in the management of high-risk localised and metastatic prostate cancer Age-dependent expression of immune-privilege and proliferation-related molecules on porcine Sertoli cells Alterations of senescence biomarkers in human cells by exposure to CrVI in vivo and in vitro An evaluation of clusterin antisense inhibitor OGX-011 in combination with the second-generation antiandrogen MDV3100 in a castrate-resistant prostate cancer model Analysis of a Urinary Biomarker Panel for Incident Kidney Disease and Clinical Outcomes Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy. Androgens and prostate cancer. Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells Anti-apoptotic phenotypes of cholestan-3β,5α,6β-triol-resistant human cholangiocytes: characteristics contributing to the genesis of cholangiocarcinoma. Anticlusterin treatment of breast cancer cells increases the 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity. Antisense oligodeoxynucleotide therapy for bladder cancer: Recent advances and future prospects Antisense oligodeoxynucleotide therapy for prostate cancer targeting antiapoptotic genes involved in the mechanism mediating progression to androgen independence Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro. Apoptosis and molecular targeting therapy in cancer Apoptosis regulation in the mammary gland Applying proteomic technology to clinical virology Aptamers Selected to Postoperative Lung Adenocarcinoma Detect Circulating Tumor Cells in Human Blood. Association of Vimentin overexpression and hepatocellular carcinoma metastasis ATM regulates insulin-like growth factor 1-secretory clusterin (IGF-1-sCLU) expression that protects cells against senescence. ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability. AUA Annual Meeting Program Abstracts 2012 bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Biomarkers for therapeutic response in cervical cancer Biomarkers: Saliva proteomics is a promising tool to study Sjögren syndrome B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Bone metastases in hepatocellular carcinoma: an emerging issue. Ca(2+) depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells [5] 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 Calcium in the prevention of colorectal cancer Castrate-resistant prostate cancer: therapeutic strategies. Castration-resistant prostate cancer: current and emerging treatment strategies. Castration-resistant prostate cancer: Novel therapeutics pre- or post-taxane administration Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Changes of transthyretin and clusterin after androgen ablation therapy and correlation with prostate cancer malignancy. Chapter 3: The shifting balance between CLU forms during tumor progression. Chapter 4: Regulation of Clusterin activity by calcium. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. Characterization of Interaction Protein for Osteosarcoma Related Protein IEX-1 Chemo- and radiotherapy induce common apoptotic mediators in Hodgkin's Lymphoma Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer Clinical proteomics in cancer research Clinical significance of clusterin expression in pancreatic adenocarcinoma. Clinicopathologic characteristics of inflammatory pseudotumor-like follicular dendritic cell sarcoma. Clinicopathological impact of novel biomarkers for diagnosis and prognosis of renal cell carcinoma Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models CLU blocks HDACI-mediated killing of neuroblastoma. CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for HSP90 inhibition in prostate cancer CLU inhibition using OGX-011 is a new adjuvant therapeutic strategy for HSP90 inhibition in prostate cancer Clusterin (ApoJ), COMMD1 and ApoE: Molecular chaperones for quality control of the copper transporting P-type ATPases, ATP7A and ATP7B Clusterin (Apolipoprotein J), a molecular chaperone that facilitates degradation of the copper-ATPases ATP7A and ATP7B 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 Clusterin (CLU) and lung cancer. Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro. Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. Clusterin and chemoresistance. Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control. Clusterin and IGFBPs as antisense targets in prostate cancer. Clusterin antisense inhibitor OGX-011 synergizes activity of second generation anti-androgen, MDV3100, in castrate resistant prostate cancer model Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Clusterin as a potential marker in distinguishing cervical neoplasia Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. Clusterin downregulation sensitize prostate cancer cells to taxane by modulating mitosis Clusterin expression and apoptosis in transitional cell carcinoma of the bladder Clusterin expression and localization are affected by rituximab and doxorubicin treatment in non-hodgkin lymphoma cells and B lymphocytes Clusterin expression and univariate analysis of overall survival in human breast cancer. Clusterin expression correlates with stage and presence of large cells in mycosis fungoides. Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy. Clusterin expression is associated with decreased disease-free survival of patients with colorectal carcinomas. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Clusterin expression predicts survival of invasive cervical cancer 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 patients treated with radical hysterectomy and systematic lymphadenectomy. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma. Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival. Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. Clusterin gene is predominantly regulated by histone modifications in human colon cancer and ectopic expression of the nuclear isoform induces cell death. Clusterin immunoexpression and its clinical significance in patients with non-small cell lung cancer. Clusterin immunoreactivity as a predictive factor for progression of non-muscle-invasive bladder carcinoma. Clusterin inhibition to enhance tumor chemosensitivity in systemic tumors Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. Clusterin interaction with Bcl-x(L) is associated with seizure-induced neuronal death Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel. Clusterin Is a Short Half-Life, Poly-Ubiquitinated Protein, Which Controls the Fate of Prostate Cancer Cells Clusterin is a ubiquitin binding protein involved in Murr1 and 1-kB proteasomal degradation to confer cell survival in prostate cancer Clusterin knockdown synergizes activity of second generation anti-androgen, MDV3100, through enhancing AR degradation and repression of FKBP52 in castrate resistant prostate cancer model Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells Clusterin overexpression and relapse-free survival in breast cancer. Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Clusterin over-expression modulates proapoptotic and antiproliferative effects of 1,25(OH)2D3 in prostate cancer cells in vitro. 109 Clusterin protects hepatocellular carcinoma cells from endoplasmic reticulum stress induced apoptosis through GRP78. 110 Clusterin regulates drug-resistance in melanoma cells. 111 Clusterin silencing inhibits proliferation and reduces invasion in human laryngeal squamous carcinoma cells. 112 Clusterin silencing sensitizes pancreatic cancer MIA-PaCa-2 cells to gmcitabine via regulation of NF-kB/Bcl-2 signaling. 113 Clusterin up-regulation following sub-lethal oxidative stress and lipid peroxidation in human neuroblastoma cells. 114 Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. 115 Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma. 116 Clusterin: the missing link in the calcium-dependent resistance of cancer cells to apoptogenic stimuli. 117 Coexpression of multiple Sertoli cell and Leydig cell marker genes in the spontaneous testicular tumor of F344 rat: evidence for phenotypical bifurcation of the interstitial cell tumor. 118 Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells. 119 Combined use of antisense oligonucleotides and chemotherapeutics in the treatment of refractory prostate cancer 120 Comparative analysis of the human urinary proteome by 1D SDS-PAGE and chip-HPLC-MS/MS identification of the AACT putative urinary biomarker 121 Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. 122 Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. 123 Control of tumor progression by maintenance of apoptosis 124 Copper induces cellular senescence in human glioblastoma multiforme cells through downregulation of Bmi-1. 125 Correlation of Clusterin Expression and Apoptosis in Prostate Cancer and Benign Hyperplastic Tissues 126 Correlation of clusterin expression to prognosis of bladder carcinoma. 127 Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. 128 Co-targeting ROS and CLU-mediated stress response using SMIP004 (a novel inducer of ROS and cancer cell selective apoptosis) and OGX-011 in MDV3100-resistant, castrate-resistant prostate cancer 129 COX proportional hazards model analysis on breast cancer prognosis and the correlation with clusterin expression 130 CRM1 Protein-mediated Regulation of Nuclear Clusterin (nCLU), an Ionizing Radiation-stimulated, Bax-dependent Pro-death Factor 131 Current and potential treatments for cervical cancer 132 Current proteomic analysis and post-translational modifications of biomarkers in human lung cancer materials 133 Custirsen (OGX-011): A second-generation antisense inhibitor of clusterin for the treatment of cancer 134 Custirsen (OGX-011): A second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer 135 Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer 136 Custirsen sodium: Clusterin-targeting antisense therapy oncolytic 137 Cyclin D, cytochrome P4504F2 and lipid peroxidation levels segregate good and poor stage II tumours 138 Cytoplasmic Clusterin expression correlates with pancreatic neuroendocrine tumor size and pathological stage. 139 Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. 140 Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. 141 Dendritic cell neoplasms: An overview 142 Detecting soluble Clusterin in in-vitro and in-vivo models of prostate cancer 143 Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy 144 Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. 145 Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer. 146 Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma. 147 Differential effects of clusterin/apolipoprotein J on cellular growth and survival. 148 Differential expression of clusterin according to histological type of endometrial carcinoma. 149 Differential expression of haptoglobin isoforms in chronic active hepatitis, cirrhosis and HCC related to HBV infection. 150 Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics 151 Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. 152 Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. 153 Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling. 154 DNA methylation or histone modification status in metastasis and angiogenesis-related genes: A new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability 155 Downregulating sCLU Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Gemcitabine by Activating the Intrinsic Apoptosis Pathway 156 Downregulation of clusterin expression in human testicular seminoma. 157 Downregulation of clusterin mediates sensitivity to protein kinase inhibitors in breast cancer cells. 158 Downregulation of Hsp27 using OGX-427 induces ER stress and potentiates Hsp90 inhibitors to delay castrate resistant prostate cancer 159 Dynamic Expression Patterns of Differential Proteins during Early Invasion of Hepatocellular Carcinoma 160 Effect of tumour progression on the androgenic regulation of the androgen receptor, TRPM-2 and YPT1 genes in the Shionogi carcinoma. 161 Effects of clusterin knock down on prostate cancer progression in the TRAMP model 162 Effects of clusterin over-expression on metastatic progression and therapy in breast cancer. 163 Effects of down-regulation of clusterin by small interference RNA on human acute myeloid leukemia cells. 164 Effects of female sex hormones on clusterin expression and paclitaxel re-sistance in endometrial cancer cell lines 165 Effects of navelbine and docetaxel on gene expression in lung cancer cell strains. 166 Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. 167 Elevated lipid peroxidation and cyclin D1 levels correlate with poor survival and disease recurrence in stage II tumours 168 Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review). 169 Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro. 170 Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. 171 Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. 172 Enhanced radiosensitivity by inhibition of the anti-apoptotic gene 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 clusterin using antisense oligodeoxynucleotide in a human bladder cancer model. Epithelial-to-mesenchymal transition in renal neoplasms ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer. ERCC1, FLK-1, clusterin, and HER2/neu overexpression and risk of recurrence in patients (PTS) treated with cystectomy for muscle-invasive urothelial carcinoma of the bladder (UC) Ethylenediaminetetraacetic acid affects subcellular expression of clusterin protein in human colon adenocarcinoma COLO 205 cell line. Evaluation of 9 different prognostic markers in patients after radical cystectomy Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis. Evidence-based guidelines for precision risk stratification- based screening (PRSBS) for colorectal cancer: Lessons learned from the us armed forces: Consensus and future directions Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. Expression and clinical significance of YKL-40 protein in epithelial ovarian carcinoma tissues Expression and significance of clusterin in non-small cell lung cancer Expression of clusterin in human pancreatic cancer. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Expression of clusterin, an antiapoptotic molecule, predicts survival of patients with cervical cancer Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: Impact on clinicopathological outcomes in patients undergoing radical nephrectomy Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy. 192 Expression of the antiapoptotic proteins clusterin and bcl-2 in laryngeal squamous cell carcinomas. 193 Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. 194 External validation suggests integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas 195 EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. 196 Far-infrared radiation inhibits proliferation, migration, and angiogenesis of human umbilical vein endothelial cells by suppressing secretory clusterin levels. 197 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC) 198 Follicular dendritic cell sarcoma: a clinicopathologic study of 8 cases. 199 Folliculocentric B-cell-rich follicular dendritic cells sarcoma: A hitherto unreported morphological variant mimicking lymphoproliferative disorders 200 Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. 201 From new targets to new drugs in prostate cancer - Other targets 202 Functional analysis of clusterin/apolipoprotein J in cellular death induced by severe genotoxic stress. 203 Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome 204 Gene products involved in metastasis of bladder cancer 205 Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. 206 Genetic variants conferring susceptibility to Alzheimer's disease in the general population; do they also predispose to dementia in Down's syndrome. 207 Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS) 208 Global effects of anchorage on gene expression during mammary carcinoma cell growth reveal role of tumor necrosis factor-related apoptosis-inducing ligand in anoikis. 209 GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer. 210 Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer. 211 Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential. 212 Heat shock proteins in prostate cancer: From tumorigenesis to the clinic 213 Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. 214 Hepatitis D and hepatocellular carcinoma. 215 Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells. 216 Heterogeneity in mouse spasmolytic polypeptide-expressing metaplasia lineages identifies markers of metaplastic progression. 217 High clusterin expression correlates with a poor outcome in stage II colorectal cancers. 218 HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells. 219 Hsps and aging 220 Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. 221 Human nuclear clusterin mediates apoptosis by interacting with Bcl-XL through C-terminal coiled coil domain. 222 Human skeletal myoblasts spontaneously activate allogeneic complement but are resistant to killing. 223 Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer. 224 Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma. 225 Identification of CLUAP1 as a human osteosarcoma tumor-associated antigen recognized by the humoral immune system. 226 Identification of critical genes and gene interaction networks that mediate osteosarcoma metastasis to the lungs. 227 Identification of host-immune response protein candidates in the sera of human oral squamous cell carcinoma patients. 228 Identification of molecular markers of radiation-induced toxicity in patients undergoing breast conserving therapy 229 Identification of new genes downregulated in prostate cancer and investigation of their effects on prognosis. 230 Identification of O-glycosylated proteins that are aberrantly excreted in the urine of patients with early stage ovarian cancer. 231 Identification of ovarian genes regulated by follicle-stimulating hormone (Fsh) in vitro during early secondary oocyte growth in coho salmon. 232 Identification of stromal cell products that interact with pre-B cells. 233 IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin. 234 Immunohistochemical stains of proliferating cell nuclear antigen, insulin-like growth factor 2 and clusterin help distinguish malignant from benign liver nodular lesions. 235 Immunophenotypic features of metastatic lymph node tumors to predict recurrence in N2 lung squamous cell carcinoma. 236 Impact of gene expression profiling in lymphoma diagnosis and prognosis 237 Increase in clusterin forms part of the stress response in Hodgkin's lymphoma. 238 Increased cell death in rat blastocysts exposed to maternal diabetes in utero and to high glucose or tumor necrosis factor-alpha in vitro. 239 Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. 240 Induction of the TRPM-2 gene in cells undergoing programmed death. 241 Inflammatory myofibroblastic tumors in childhood: a report from the Italian Cooperative Group studies. 242 Inflammatory myofibroblastic tumors of the urinary bladder: a systematic review. 243 Inflammatory pseudotumor-like follicular dendritic cell sarcoma : clinicopathological features and prognosis study of 6 cases 244 Influence of silencing clusterin by RNAi on radiosensitivity of human ovarian carcinoma SKOV3 cell-line 245 Influence of stress on extracellular matrix and integrin biology 246 Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. 247 Inhibition of androgen receptor expression with small interfering RNA enhances cancer cell apoptosis by suppressing survival factors in androgen insensitive, late stage LNCaP cells. 248 Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. 249 Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer 250 Interaction of a putative BH3 domain of clusterin with anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy 251 Interleukin-6 affects cell death escaping mechanisms acting on Bax-Ku70-Clusterin interactions in human colon cancer progression. 252 Intermittent therapy for prostate cancer 253 Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1. 254 Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. 255 Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential 256 Involvement of Oxidative Stress in Occurrence of Relapses in Multiple Sclerosis: The Spectrum of Oxidatively Modified Serum Proteins Detected by Proteomics and Redox Proteomics Analysis 257 IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. 258 Knockdown of clusterin expression increases the in vitro sensitivity of human prostate cancer cells to paclitaxel. 259 Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. 260 Label-free quantitative proteomic analysis of benzo(a)pyrene-transformed 16HBE cells serum-free culture supernatant and xenografted nude mice sera 261 LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma 262 Lentivirus-mediated RNA interference of clusterin enhances the chemosensitivity of EJ bladder cancer cells to epirubicin in vitro. 263 Lessons from in-vivo models of castration-resistant prostate cancer 264 Levamisole induced apoptosis in cultured vascular endothelial cells. 265 Lipid rafts mediate epigallocatechin-3-gallate- and green tea extract-dependent viability of human colon adenocarcinoma COLO 205 cells; clusterin affects lipid rafts-associated signaling pathways. 266 Longevity assurance molecular pathways in human cells 267 Loss of clusterin expression worsens renal ischemia-reperfusion injury. 268 Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGFβ1 signaling to confer a pro-survival bystander effect. 269 Lunasin induces apoptosis and modifies the expression of genes associated with extracellular matrix and cell adhesion in human metastatic colon cancer cells. 270 Lymphotoxin-beta receptor-dependent genes in lymph node and follicular dendritic cell transcriptomes. 271 Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer 272 Mechanisms of platelet-stimulated colon cancer invasion: role of clusterin and thrombospondin 1 in regulation of the P38MAPK-MMP-9 pathway. 273 Mechanisms of the development of androgen independence in prostate cancer 274 Metastasin leads to poor prognosis of hepatocellular carcinoma through partly inducing EMT 275 Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): Implications to the therapy of pancreatic adenocarcinoma 276 Molecular Alterations Associated With Bladder Cancer Progression 277 Molecular and genetic profiling of prostate cancer: Implications for future therapy 278 Molecular characterization of the leukemic niche in chronic myeloid leukemia (CML) and evaluation of a leukemia / niche cross-talk 279 Molecular consequences of activated microglia in the brain: overactivation induces apoptosis. 280 Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?) 281 Molecular mechanisms of cellular stress responses in gastric cancer 282 Mouse mammary tumor virus suppresses apoptosis of mammary epithelial cells through ITAM-mediated signaling 283 Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer. 284 Neuroblastoma genetics and phenotype: A tale of heterogeneity 285 Neuroblastoma models for insights into tumorigenesis and new therapies 286 New developments in castrate-resistant prostate cancer. 287 New markers in ovarian cancer 288 NF-kB is not directly responsible for photoresistance induced by fractionated light delivery in HT-29 colon adenocarcinoma cells. 289 Nonmetastatic renal-cell carcinoma: Is it really possible to define rational guidelines for post-treatment follow-up? 290 Non-small cell lung carcinoma cell motility, Rac activation and metastatic dissemination are mediated by protein kinase C epsilon 291 Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient 292 Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma. 293 Novel molecular targets for the therapy of castration-resistant prostate cancer. 294 Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells 295 Novel targeted agents on the horizon for castration-resistant prostate cancer 296 Novel targets and approaches in advanced prostate cancer 297 Novel therapeutic strategies following docetaxel-based chemotherapy in castration-resistant prostate cancer 298 Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity 299 Novel therapeutics in the treatment of bladder cancer 300 Novel therapies for metastatic castrate-resistant prostate cancer. 301 Nuclear clusterin accumulation during heat shock response: implications for cell survival and thermo-tolerance induction in immortalized and prostate cancer cells. 302 Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. 303 Oncogenic role of clusterin overexpression in multistage colorectal tumorigenesis and progression. 304 Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. 305 Overall survival according to tumoral clusterin expression in breast cancer 306 Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays. 307 Overexpression of clusterin in human breast carcinoma. 308 Overexpression of clusterin in human hepatocellular carcinoma. 309 Overexpression of clusterin in ovarian cancer is correlated with impaired survival. 310 Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. 311 Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer. 312 Overexpression of glial cell line-derived neurotrophic factor induces genes regulating migration and differentiation of neuronal progenitor cells 313 Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. 314 Overview how adenocarcinoma cancer cells avoid immune- and chemotherapy-induced apoptosis. 315 PACAP inhibits tumor growth and interferes with clusterin in cervical carcinomas. 316 Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNγ-induced apoptosis 317 Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma. 318 Pathways of chemotherapy resistance in castration-resistant prostate cancer 319 PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus 320 Peripheral T-cell Lymphomas 321 Peroxiredoxin 2: a potential biomarker for early diagnosis of hepatitis B virus related liver fibrosis identified by proteomic analysis of the plasma. 322 Peroxisome proliferator-activated receptors and alzheimer's disease: Hitting the blood-brain barrier 323 Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. 324 Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. 325 Phase III SYNERGY trial: Docetaxel +/-custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis 326 Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study. 327 Plasma proteome analysis of cervical intraepithelial neoplasia and cervical squamous cell carcinoma. 328 Plasma proteomics analysis of tamoxifen resistance in breast cancer. 329 Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis 330 Platelet proteins clusterin, cofilin-1 and glutathione synthetase as biomarker for early detection of colorectal cancer 331 Platelet-protein-profiling of healthy controls and patients with earlyand late-stage colorectal cancer 332 Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. 333 Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer 334 Potential use of custirsen to treat prostate cancer. 335 Potential utilization of bystander/abscopal-mediated signal transduction events in the treatment of solid tumors 336 Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. 337 Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. 338 Profilin 1 is a potential biomarker for bladder cancer aggressiveness. 339 Prognostic factors in 105 Japanese cases of mycosis fungoides and Sé zary syndrome: clusterin expression as a novel prognostic factor. 340 Prognostic impact of polymorphisms in the MYBL2 interacting genes in breast cancer. 341 Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches 342 Prognostic role of clusterin in resected adenocarcinomas of the lung. 343 Prognostic significance of clusterin expression in advanced-stage cervical cancer treated with curative intended radiotherapy. 344 Prognostic significance of clusterin immunoreactivity in breast cancer. 345 Prostate cancer: All aspects 346 Prostatic androgen repressed message-1 (PARM-1) may play a role in prostatic cell immortalisation 347 Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner 348 Protein expression profiles in adenocarcinomas and squamous cell carcinomas of the lung generated using tissue microarrays 349 Protein identification from dried nipple aspirate fluid on Guthrie cards using mass spectrometry 350 Proteomic analysis of renal diseases: Unraveling the pathophysiology and biomarker discovery 351 Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis. 352 Proteomic profiles of desmoid tumors and osteosarcoma of bone and somatic soft tissue 353 Proteomic profiling of paraffin-embedded samples identifies metaplasia-specific and early-stage gastric cancer biomarkers. 354 Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers 355 Putative circulating markers of the early and advanced stages of breast cancer identified by high-resolution label-free proteomics. 356 Radiation-induced apoptosis of human prostate cancer cells is independent of mutant p53 overexpression. 357 Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. 358 Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. 359 Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. 360 Recent advances in second-line treatment of castration-resistant prostate cancer. 361 Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. 362 Regulation and functions of clusterin: A protector against stress 363 Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells. 364 Regulation of the expression of CLU isoforms in endometrial proliferative diseases. 365 Relationship between variant forms of estrogen receptor RNA and an apoptosis-related RNA, TRPM-2, with survival in patients with breast cancer. 366 Relative quantitation of proteins in expressed prostatic secretion with a stable isotope labeled secretome standard 367 Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines 368 Research in castrationresistant prostate cancer: What does the future hold? 369 Research update 370 Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments. 371 Reversible inactivation of superoxide-sensitive aconitase in Abeta1-42-treated neuronal cell lines. 372 Rituximab-treated B lymphocytes and non-hodgkin lymphoma cells feature a distinct clusterin expression profile 373 RNA interference-mediated secretory clusterin gene silencing inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cells. 374 Role of complement regulatory proteins in the survival of murine allo-transplanted Sertoli cells. 375 Role of genomics-based strategies in overcoming chemotherapeutic resistance. 376 Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells 377 Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer. 378 Sclusterin in tumor T cell infiltrate: A new role in tumour immune escaping? 379 Screening serum biomarkers of hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry 380 sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients. 381 Secreted CLU is associated with the initiation of triple-negative breast cancer. 382 Secreted proteins as a fundamental source for biomarker discovery 383 Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer. 384 Selected molecular factors associated with metastases of ovarian cancer 385 Selenium-responsive proteins in the sera of selenium-enriched yeast-supplemented healthy African American and Caucasian men. 386 Se-methylselenocysteine inhibits apoptosis induced by clusterin knockdown in neuroblastoma N2a and SH-SY5Y cell lines. 387 Seminal plasma as a diagnostic fluid for male reproductive system disorders 388 Serological autoantibody profiling using protein arrays distinguish bladder cancer patients from controls 389 Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. 390 Serum amyloid A, clusterin and apolipoprotein A-I serum levels related to metastatic progression in melanoma patients 391 Serum and tissue profiling in bladder cancer combining protein and tissue arrays. 392 Serum clusterin and vitronectin in alcoholic cirrhosis. 393 Serum clusterin as a tumor marker and prognostic factor for patients with esophageal cancer. 394 Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. 395 Serum Proteomic Approach for the Identification of Serum Biomarkers Contributed by Oral Squamous Cell Carcinoma and Host Tissue Microenvironment 396 Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation 397 Significance of Aurora-A expression in renal cell carcinoma 398 Significance of clusterin expression in patients with hepatocellular carcinoma undergoing hepatic resection 399 Significance of epithelial-mesenchymal transition markers in the prognosis of patients with renal cell carcinoma who underwent radical nephrectomy 400 Silencing FLIP(L) modifies TNF-induced apoptotic protein expression 401 siRNA lipid nanoparticle potently silences clusterin and delays progression when combined with androgen receptor cotargeting in enzalutamide-resistant prostate cancer 402 Sliencing of secretory clusterin blocks tumor growth and metastasis of hepatocellular carcinoma HCCLM3 cells 403 Small heat shock proteins in cancer therapy and prognosis. 404 Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer. 405 Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer 406 SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC) 407 Tamoxifen Suppresses Clusterin Level through Akt Inactivation and Proteasome Degradation in Human Prostate Cancer Cells 408 Targeted knockdown of clusterin sensitizes pancreatic cancer MIA-PaCa-2 cell to gmcitabine treatment by inactivation of NF-κB/BCL-2 409 Targeted plasma proteome profiling for early prediction of chemotherapy response and toxicity in colorectal cancer (CRC) 410 Targeted therapies for prostate cancer 411 Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer. Beyond the Androgen Receptor 412 Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. 413 Targeting cell survival genes using antisense oligonucleotides to improve chemo- and hormonal-therapies in prostate cancer 414 Targeting heat shock proteins in metastatic castration-resistant prostate cancer 415 Targeting stress-induced molecular chaperones CLU and Hsp27 to inhibit EMT and metastases 416 Targeting the apoptosis pathway in prostate cancer 417 Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. 418 Temperature-dependent modification and activation of B-MYB: implications for cell survival. 419 The clusterin paradigm in prostate and breast carcinogenesis. 420 The current status of research in anti-apoptosis gene of breast cancer 421 The detection of protein expression of clusterin and Ki-67 and the status of cell apoptosis in bladder transitional cell carcinoma. 422 The discovery of putative urine markers for the specific detection of prostate tumor by integrative mining of public genomic profiles 423 The Editor's Choice 424 The effect of overexpression of rat clusterin in L929 fibroblasts 425 The emerging role of anti-angiogenic therapy in ovarian cancer (review) 426 The inhibition of angiogenesis by antisense oligonucleotides to clusterin. 427 The interleukin-6 family cytokine interleukin-11 regulates homeostatic epithelial cell turnover and promotes gastric tumor development. 428 The molecular chaperone apolipoprotein J/clusterin as a sensor of oxidative stress: implications in therapeutic approaches - a mini-review. 429 The new anti-oncogene clusterin and the molecular profiling of prostate cancer progression and prognosis. 430 The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. 431 The prognostic significance of Clusterin expression in ovarian cancer 432 The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. 433 The relationship of clusterin expression and Ki-67 labeling index with clinicopathologic factors in human transitional cell carcinoma 434 The relationship of clusterin expression with Ki-67 expression and clinicopathological factors in human renal cell carcinoma 435 The role of clusterin (CLU) in malignant transformation and drug resistance in breast carcinomas. 436 The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target. 437 The role of heat shock proteins in bladder cancer. 438 The role of stress proteins in prostate cancer. 439 The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60. 440 Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies 441 Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. 442 Tumor-derived secretory clusterin induces epithelial-mesenchymal transition and facilitates hepatocellular carcinoma metastasis. 443 Update on options for treatment of metastatic castration-resistant prostate cancer 444 Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. 445 Upregulation of clusterin/apolipoprotein J in lactacystin-treated SH-SY5Y cells. 446 Urological oncology in Europe: Research highlights from the XVIIth Congress of the European Association of Urology Birmingham, UK, February 23-26, 2002 447 Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. 448 Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. 449 Value of clusterin expression in pathologic diagnosis and histogenesis of giant cell tumor of tendon sheath. 450 Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. 451 VEGF-A165A and IL-6 in human colon cancer: A microenvironment cooperation leading to cell death escape through microRNAS dysregulation 452 What's hot in the prostate? 453 When X-ray-inducible proteins meet DNA double strand break repair. 454 Zinc sensing receptor signaling, mediated by GPR39, reduces butyrate-induced cell death in HT29 colonocytes via upregulation of clusterin.